The study of genetics heavily relies on the idea that alleles, the versions of genes that make up a chromosome, are either recessive or dominant. The presence of a dominant allele means that this ...

Zevaskyn is supplied as a single-dose of up to 12 cellular sheets consisting of a patient's own viable, gene-modified cells that contain functional copies of the COL7A1 gene, which express ...

Please provide your email address to receive an email when new articles are posted on . Recessive dystrophic epidermolysis bullosa is a rare and serious condition. Zevaskyn is the first FDA ...

Prademagene zamikeracel (Zevaskyn) is the first and only cell-based gene therapy for wound treatment in patients with recessive dystrophic epidermolysis bullosa. The approval is based on the ...

the first cell-based gene therapy for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a serious and debilitating genetic skin disease. There is no cure ...

On April 25, 2025, the FDA approved prademagene zamikeracel (Zevaskyn; Abeona Therapeutics) (pz-cel), as the first and only autologous, gene-modified cell therapy for adult and pediatric patients with ...